Graphene Brain Chip Pioneers Cancer Cell Localization

Updated on: November 07,2024

Graphene Brain Chip Pioneers Cancer Cell Localization

Updated on:November 07,2024

New AI model detects 90% of lymphatic cancer cases

by Chalmers University of TechnologyCredit:The Lancet Digital Health(2023). DOI: 10.1016/S2589-7500(23)00203-0Medical image analysis using AI has developed rapidly in recent years. No

Updated on: March 20,2024

New AI model detects 90% of lymphatic cancer cases

by Chalmers University of TechnologyCredit:The Lancet Digital Health(2023). DOI: 10.1016/S2589-7500(23)00203-0Medical image analysis using AI has developed rapidly in recent years. No

Updated on:March 20,2024

Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely rec

Updated on: December 21,2023

Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely rec

Updated on:December 21,2023

Financial toxicity after robotic prostate cancer surgery: Younger patients at higher risk

byWolters Kluwer HealthPatient-reported outcomes measures changes during follow-up for groups (a-d). EF indicates erectile function domain; FT, financial toxicity; ICIQ-SF, International Consult

Updated on: December 25,2023

Financial toxicity after robotic prostate cancer surgery: Younger patients at higher risk

byWolters Kluwer HealthPatient-reported outcomes measures changes during follow-up for groups (a-d). EF indicates erectile function domain; FT, financial toxicity; ICIQ-SF, International Consult

Updated on:December 25,2023

Deep learning–based virtual staining of tissue facilitates rapid assessment of breast cancer biomarker

byUCLA Engineering Institute for Technology AdvancementVirtual HER2 staining of unlabeled breast tissue sections using deep learning. Credit: Ozcan Lab @ UCLA.Breast cancer is one the leading ca

Updated on: December 25,2023

Deep learning–based virtual staining of tissue facilitates rapid assessment of breast cancer biomarker

byUCLA Engineering Institute for Technology AdvancementVirtual HER2 staining of unlabeled breast tissue sections using deep learning. Credit: Ozcan Lab @ UCLA.Breast cancer is one the leading ca

Updated on:December 25,2023

NCI-MATCH: T-DM1 shows promising activity in salivary gland cancer

by ECOG-ACRIN Cancer Research GroupDr. Komal Jhaveri of Memorial Sloan Kettering Cancer Center in New York is the lead researcher for the NCI-MATCH precision medicine clinical trial's treatment ar

Updated on: December 20,2023

NCI-MATCH: T-DM1 shows promising activity in salivary gland cancer

by ECOG-ACRIN Cancer Research GroupDr. Komal Jhaveri of Memorial Sloan Kettering Cancer Center in New York is the lead researcher for the NCI-MATCH precision medicine clinical trial's treatment ar

Updated on:December 20,2023

Research identifies new route for tackling drug resistance in skin cancer cells

byQueen Mary, University of LondonA drug-resistant melanoma cell that has altered its cytoskeleton. Credit: Queen Mary University of LondonResearchers have found that melanoma cells fight anti-c

Updated on: December 20,2023

Research identifies new route for tackling drug resistance in skin cancer cells

byQueen Mary, University of LondonA drug-resistant melanoma cell that has altered its cytoskeleton. Credit: Queen Mary University of LondonResearchers have found that melanoma cells fight anti-c

Updated on:December 20,2023

Breast cancer risk from menopause hormones may last decades

by Marilynn MarchioneIn this May 6, 2010 file photo, a radiologist checks mammograms in in Los Angeles. Women who use certain types of hormones after menopause still have an increased risk of developi

Updated on: December 22,2023

Breast cancer risk from menopause hormones may last decades

by Marilynn MarchioneIn this May 6, 2010 file photo, a radiologist checks mammograms in in Los Angeles. Women who use certain types of hormones after menopause still have an increased risk of developi

Updated on:December 22,2023

Breast cancer patients to be evaluated for genetic testing

byVanderbilt University Medical CenterCredit: CC0 Public DomainAccording to a statement on behalf of the American College of Medical Genetics and Genomics (ACMG) published Dec. 13 in the organiz

Updated on: December 22,2023

Breast cancer patients to be evaluated for genetic testing

byVanderbilt University Medical CenterCredit: CC0 Public DomainAccording to a statement on behalf of the American College of Medical Genetics and Genomics (ACMG) published Dec. 13 in the organiz

Updated on:December 22,2023

Scientists develop new targeted therapeutic strategies to fight liver metastasis

by Qiu Rong, University of Science and Technology of ChinaGraphical abstract. Credit:Journal of Clinical Investigation(2023). DOI: 10.1172/JCI157937The research group led by Prof. Zeng Zhu

Updated on: December 27,2023

Scientists develop new targeted therapeutic strategies to fight liver metastasis

by Qiu Rong, University of Science and Technology of ChinaGraphical abstract. Credit:Journal of Clinical Investigation(2023). DOI: 10.1172/JCI157937The research group led by Prof. Zeng Zhu

Updated on:December 27,2023

Falling PSA levels found to predict longer survival in prostate cancer patients at high risk of metastases

byWolters Kluwer HealthTwelve-month landmark analysis of overall survival (OS) by prostate-specific antigen (PSA) decline subgroup for enzalutamide-treated men. Data cutoff: October 15, 2019. Cr

Updated on: January 02,2024

Falling PSA levels found to predict longer survival in prostate cancer patients at high risk of metastases

byWolters Kluwer HealthTwelve-month landmark analysis of overall survival (OS) by prostate-specific antigen (PSA) decline subgroup for enzalutamide-treated men. Data cutoff: October 15, 2019. Cr

Updated on:January 02,2024

Adding capivasertib to fulvestrant improves progression-free survival of hormone receptor-positive breast cancer

byAmerican Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainIn patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of th

Updated on: December 26,2023

Adding capivasertib to fulvestrant improves progression-free survival of hormone receptor-positive breast cancer

byAmerican Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainIn patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of th

Updated on:December 26,2023